Dynamics
Advanced Innovation and R&D Platform
· We are in possession of 5 authenticated technical platforms of vaccines for human use. Each platform is provided with at least one vaccine product subjecting to commercialization or development.
· 23 innovative vaccines under development are targeted at 13 diseases.
· Products under production and development cover top 10 vaccine products worldwide (global sales statistics for the year of 2020), enjoying a large market space.
· One of the first manufacturing enterprises with P3 laboratory in China according to the 14th Five-Year Plan for National Economic and Social Development.
AIM Vaccine
Stock Code：06188.HK
-
0.000
HKSE Market Value（million）
-
0.000
Spot Price (HKD)
-
0.000
Highest Today (HKD)
-
0.000
Lowest Today (HKD)
As of: （Beijing Time). The offer may have a delay of 15 minutes or above.
Information/data source: SINA FINANCE
History
-
We acquired 50.1546% equities of Liverna to further accelerate research of mRNA COVID-19 vaccine and production layout.
-
We completed restructuring, and changed to corporate name to AIM Vaccine Co., Ltd.
In the same year, we acquired 49% equities of AIM Explorer and 20% equities of Rong’an Biology. Thus, AIM Explorer and Rong’an Biology became two wholly owned subsidiaries of AIM Vaccine.
-
We obtained approval of new drug application for MPSV4 in October, 2018.
We obtained GMP certificate as required by production of MPSV4 in December, 2018.
-
During the period from September, 2017 to January, 2019, we acquired all equities of AIM Weixin. As a result of it, AIM Weixin became a wholly owned subsidiary of AIM Vaccine.
AIM Weixin obtained approval of new drug application for vaccine targeted at hemorrhagic fever with renal syndrome in September, 2007 and GMP certificate as required by production in February, 2008. Previously, it also obtained approval of new drug application for mumps vaccine in October, 2004 and GMP certificate as required by production of the same vaccine in January, 2005.
-
We acquired all equities of AIM Kanghuai during the period from November, 2016 to December, 2017. As a result of it, AIM Kanghuai became a wholly owned subsidiary of AIM Vaccine.
AIM Kanghuai obtained approval of new drug application for HBV vaccine inactivated (human diploid cell) in April, 2015. Later, it obtained approval from National Medical Products Administration for production of other types of HBV vaccines inactivated (human diploid cell) in January, 2016.
-
We acquired entire equity interests of AIM Hanxin
AIM Hanxin respectively obtained NDA for 10ug/0.5ml and 20ug/0.5ml recombinant HBV vaccine (Hansenula Polymorpha) from National Medical Products Administration in March, 2004 and August, 2013, and obtained GMP production certificate in June, 2004.
AIM Vaccine is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from R&D, manufacturing to commercialization.
AIM Vaccine Co., Ltd. is one of the only four domestic vaccine companies with sales network covering 31 provinces, autonomous regions and municipalities. In 2020, the company realized lot release of 60 million dosages with vaccine products. It prides itself on a professional and devoted sales team consisting of more than 100 members with over a decade of pharmaceutical or vaccine sales experience, and a core business leadership team with an average of 12 years of vaccine commercialization experience at transnational pharmaceuticals as well as outstanding achievements in marketing international blockbuster vaccines (including the world’s first HPV, IPV and DTaP-IPV-Hib vaccines).
Through ten-year development, the company has established its business mode and corporate culture as characterized by inclusiveness and sustainable exploration. As a result of it, its existing businesses have been further expanded and optimized. Presently, the company has 4 authenticated wholly owned vaccine manufacturing enterprises affiliated to it, namely AIM Hissen, AIM ConVac, AIM Weixin and Rong’an Bio. The company holds controlling shares of 3 research institutes, including a R&D center, AIM Explorer as established in 2018 for provision of technical supports for initial and advanced researches by R&D departments of various plants. In 2021, AIM completed merger and acquisition of Zhuhai Lifanda Biology Co., Ltd. It is one of 3 enterprises acquired clinical trial approval of mRNA COVID-19 vaccine in China, which has established its own mRNA production and drug express delivery platform.
